Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03552536
Recruitment Status : Completed
First Posted : June 12, 2018
Last Update Posted : March 25, 2019
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : March 11, 2019
Actual Study Completion Date : March 11, 2019
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 February 14, 2020